Entera Bio (ENTX) COO Hillel Galitzer Receives Option Award

What Happened
Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd. (ENTX), received a grant of options to purchase 200,000 ordinary shares, reported on Form 4 dated August 7, 2026. The filing lists the acquisition price as $0.00 (i.e., the options were granted without cash paid by the insider). This is an equity award (derivative grant), not a share purchase or exercise.

Key Details

• Transaction date: 2026-08-07 (grant recorded and Form S-8 registering the underlying shares was filed the same day).
• Transaction type: Award/Grant of options (derivative), 200,000 option shares, acquisition price reported $0.00.
• Vesting: Options vest over a three-year schedule beginning May 7, 2026 — one-third vests on May 7, 2027; remaining two-thirds vest ratably quarterly over the subsequent two years. Full acceleration upon a Change in Control per the 2018 Equity Incentive Plan.
• Approval: Grant was approved by the Board on May 7, 2026, subject to S-8 registration (completed Aug 7, 2026).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Timeliness: Filing appears timely (transaction date and report date are the same).

Context
This was an option grant (a common form of executive compensation) rather than a market purchase or sale — it does not represent immediate buying or selling of stock. Because vesting is phased over three years and the options can accelerate on a Change in Control, the award is intended to provide retention and potential upside linkage to future company performance.